AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25638303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 24296323 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat 50 mg
Number of subjects: 23
Study 24296323 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat 100 mg
Number of subjects: 23
Study 24296323 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat 200 mg
Number of subjects: 23
Study 24296323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 20964860 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Infant Parenting (VIP) program administered in intervention schools to 1,267 participants.
Number of subjects: 2834
Study 20964860 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum received by 1,567 participants in non-intervention schools.
Number of subjects: 2834
Study 18211527 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone survey (with web follow-up for nonrespondents)
Number of subjects: 751
Study 18211527 — intervention group
Group type: COMPARATOR
Intervention: Web survey (with telephone follow-up)
Number of subjects: 751
Study 16597501 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine treatment (active group, n=33)
Number of subjects: 63
Study 16597501 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group, n=30)
Number of subjects: 63
Study 16597501 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine monotherapy (following open-label treatment)
Number of subjects: 63
Study 14664880 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy
Number of subjects: 319
Study 14664880 — intervention group
Group type: COMPARATOR
Intervention: Subtotal abdominal hysterectomy
Number of subjects: 319
Study 10751097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling endurance test A1 at 78% peak O2 consumption (VO2peak)
Number of subjects: 8
Study 10751097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling endurance test A2 at 78% peak O2 consumption (VO2peak)
Number of subjects: 8
Study 10751097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling endurance test B2 at 78% peak O2 consumption (VO2peak)
Number of subjects: 8
Study 10751097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling endurance test C2 at 78% peak O2 consumption (VO2peak)
Number of subjects: 8
Study 10751097 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing pattern of test A2
Number of subjects: 8
Study 10751097 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing pattern of test B2
Number of subjects: 8
Study 10751097 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing pattern of test C2
Number of subjects: 8
Study 8659784 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg mivacurium
Number of subjects: 41
Study 8659784 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 microg/kg mivacurium
Number of subjects: 41
Study 8659784 — intervention group
Group type: COMPARATOR
Intervention: Control group (ED95 dose of 100 microg/kg mivacurium)
Number of subjects: 41
Study 1356024 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 40
Study 1356024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1356024 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation + AMPT
Number of subjects: 40
Study 1356024 — intervention group
Group type: COMPARATOR
Intervention: Total sleep deprivation + Placebo
Number of subjects: 40
Study 1356024 — intervention group
Group type: EXPERIMENTAL
Intervention: 40.5 h of rest + AMPT
Number of subjects: 40
Study 1356024 — intervention group
Group type: COMPARATOR
Intervention: 40.5 h of rest + Placebo
Number of subjects: 40
Study 3921934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 21
Study 3921934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 21
Study 29725749 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cryotherapy at 10-12 °C (Cold-group, n=30)
Number of subjects: 60
Study 29725749 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted cryotherapy at 21 °C (Warm-group, n=30)
Number of subjects: 60
Study 29515151 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal swab samples
Number of subjects: 0
Study 29515151 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool samples
Number of subjects: 0
Study 29515151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal samples
Number of subjects: 0
Study 27832025 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg valacyclovir twice daily
Number of subjects: 20
Study 27832025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24456909 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan 160 mg/d
Number of subjects: 539
Study 24456909 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan 80 mg/d
Number of subjects: 539
Study 24456909 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d
Number of subjects: 539
Study 24456909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study 23158561 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene brachial plexus block plus general anesthesia (ISB + GA)
Number of subjects: 60
Study 23158561 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (GA)
Number of subjects: 60
Study 19158152 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 669
Study 19158152 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 669
Study 16820267 — intervention group
Group type: EXPERIMENTAL
Intervention: Project EX-4 classroom-based intervention
Number of subjects: 1097
Study 16820267 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1097
Study 15167707 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2 (IFN-alpha2) treatment
Number of subjects: 22
Study 11259325 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nateglinide (120 mg)
Number of subjects: 6
Study 11259325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nateglinide (60 mg)
Number of subjects: 6
Study 11259325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing routes
Number of subjects: 6
Study 9874434 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted blood
Number of subjects: 221
Study 9874434 — intervention group
Group type: COMPARATOR
Intervention: Packed red cells
Number of subjects: 221
Study 9874434 — intervention group
Group type: COMPARATOR
Intervention: Untransfused patients
Number of subjects: 221
Study 8067560 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored high-flow isoflurane
Number of subjects: 253
Study 8067560 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmonitored high-flow isoflurane
Number of subjects: 253
Study 8067560 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored low-flow isoflurane
Number of subjects: 253
Study 8067560 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmonitored low-flow isoflurane
Number of subjects: 253
Study 8067560 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored low-flow enflurane
Number of subjects: 253
Study 8067560 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmonitored low-flow enflurane
Number of subjects: 253
Study 2928063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bizarre imagery in immediate cued-recall condition
Number of subjects: 40
Study 2928063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bizarre imagery in delayed recall condition
Number of subjects: 40
Study 2928063 — intervention group
Group type: COMPARATOR
Intervention: Normal imagery
Number of subjects: 40
Study 2928063 — intervention group
Group type: COMPARATOR
Intervention: Mixed imagery
Number of subjects: 40
Study 31654943 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter defibrillator (S‐ICD)
Number of subjects: 0
Study 31654943 — intervention group
Group type: COMPARATOR
Intervention: Transvenous implantable cardioverter defibrillator (TV‐ICD)
Number of subjects: 0
Study 29042386 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy.me app for self-management of gout
Number of subjects: 0
Study 29042386 — intervention group
Group type: COMPARATOR
Intervention: Control group with modified Healthy.me app (only Gout Attack Diary)
Number of subjects: 0
Study 26819445 — intervention group
Group type: EXPERIMENTAL
Intervention: P4P program
Number of subjects: 1458
Study 26819445 — intervention group
Group type: COMPARATOR
Intervention: Non-P4P program
Number of subjects: 1458
Study 24103632 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA + Memantine (5 mg/day)
Number of subjects: 232
Study 24103632 — intervention group
Group type: COMPARATOR
Intervention: VPA + Pbo
Number of subjects: 232
Study 22364739 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (200 mg)
Number of subjects: 67
Study 22364739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 19562533 — intervention group
Group type: EXPERIMENTAL
Intervention: iv paracetamol 1 g preoperatively (Group I)
Number of subjects: 90
Study 19562533 — intervention group
Group type: EXPERIMENTAL
Intervention: iv paracetamol 1 g intraoperatively (Group II)
Number of subjects: 90
Study 19562533 — intervention group
Group type: COMPARATOR
Intervention: Saline as placebo (Group III)
Number of subjects: 90
Study 17659757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) treatment for 24 months
Number of subjects: 87
Study 17659757 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine with methylprednisolone (AZA) treatment for 24 months
Number of subjects: 87
Study 17659757 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 87
Study 16374010 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery with CPB (group A)
Number of subjects: 30
Study 16374010 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass surgery without CPB (OP, group B)
Number of subjects: 30
Study 12205250 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed mood at baseline
Number of subjects: 9374
Study 12205250 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed mood at baseline among those not obese at baseline
Number of subjects: 9374
Study 12205250 — intervention group
Group type: COMPARATOR
Intervention: Baseline obesity
Number of subjects: 9374
Study 12205250 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed mood at baseline among those obese at baseline
Number of subjects: 9374
Study 9595977 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (6 MIU, 30 microg) administered via single intramuscular injection
Number of subjects: 0
Study 9595977 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (6 MIU, 30 microg) administered in the placebo-controlled phase III clinical trial
Number of subjects: 0
Study 9595977 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a exposure to PLP-reactive murine T-cell lines
Number of subjects: 0
Study 9761519 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 38
Study 9761519 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 38
Study 1864026 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin hydrochloride (alpha blocker)
Number of subjects: 60
Study 1864026 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 1864026 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin hydrochloride
Number of subjects: 60
Study 7056183 — intervention group
Group type: EXPERIMENTAL
Intervention: synthetic secretin
Number of subjects: 33
Study 7056183 — intervention group
Group type: COMPARATOR
Intervention: cimetidine
Number of subjects: 33
Study 31833588 — intervention group
Group type: EXPERIMENTAL
Intervention: APPLE-Tree intervention (10-session group intervention with personalized goal-setting)
Number of subjects: 704
Study 31833588 — intervention group
Group type: COMPARATOR
Intervention: Informational control group
Number of subjects: 704
Study 31420050 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label placebo (OLP) treatment for 4 weeks
Number of subjects: 100
Study 31420050 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label placebo (OLP) treatment continued for another 4 weeks
Number of subjects: 100
Study 31420050 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 100
Study 31420050 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label placebo (OLP) treatment
Number of subjects: 100
Study 26126810 — intervention group
Group type: EXPERIMENTAL
Intervention: BEC (S‐(2‐boronoethyl)‐L‐cysteine)
Number of subjects: 30
Study 26126810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 26126810 — intervention group
Group type: EXPERIMENTAL
Intervention: PAH group
Number of subjects: 30
Study 26126810 — intervention group
Group type: EXPERIMENTAL
Intervention: BEC group
Number of subjects: 30
Study 25624374 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA‐AQ (110 μg once daily)
Number of subjects: 299
Study 25624374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 23237936 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (0.3 mg/kg) combined with mannitol (1 g/kg)
Number of subjects: 23
Study 23237936 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with mannitol (1 g/kg)
Number of subjects: 23
Study 21767149 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Chinese herbal medicine (CHM) decoctions
Number of subjects: 40
Study 21767149 — intervention group
Group type: COMPARATOR
Intervention: Placebo decoction (therapeutically inert)
Number of subjects: 40
Study 19498098 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (70 maximal voluntary actions)
Number of subjects: 24
Study 16687991 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (mean dose 25.4+/‐6.6 mg/day)
Number of subjects: 13
Study 16687991 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 13
Study 16687991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during discontinuation phase)
Number of subjects: 13
Study 15504188 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.15 mg kg(‐1)
Number of subjects: 92
Study 15504188 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.30 mg kg(‐1)
Number of subjects: 92
Study 15504188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 92
Study 11785712 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC (omeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week)
Number of subjects: 170
Study 11785712 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC (rabeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week)
Number of subjects: 170
Study 10092717 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (MgOH) administration at a ratio of 5 mg of MgOH for every 1 mg of ingested elemental iron.
Number of subjects: 16
Study 10092717 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MgOH administration).
Number of subjects: 16
Study 10092717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control).
Number of subjects: 16
Study 7707164 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting ACE inhibitors (captopril and quinapril) given twice a day
Number of subjects: 0
Study 7707164 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting ACE inhibitors (enalapril, lisinopril, benazepril, cilazapril) given once a day
Number of subjects: 0
Study 2666728 — intervention group
Group type: EXPERIMENTAL
Intervention: Kenalog
Number of subjects: 0
Study 2666728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0
Study 2666728 — intervention group
Group type: COMPARATOR
Intervention: Gordox
Number of subjects: 0
Study 2666728 — intervention group
Group type: COMPARATOR
Intervention: Polyvinylpyrrolidone
Number of subjects: 0
Study 2666728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 904549 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 g phenformin/day
Number of subjects: 22
Study 904549 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 g phenformin + 1.5 g clofibrate/day
Number of subjects: 22
Study 904549 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g clofibrate/day
Number of subjects: 22
Study 904549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31507034 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory Peer Research (PPR) intervention
Number of subjects: 10
Study 31507034 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 10
Study 27745562 — intervention group
Group type: EXPERIMENTAL
Intervention: FuF labels with in‐aisle signs explaining the labels
Number of subjects: 153
Study 27745562 — intervention group
Group type: EXPERIMENTAL
Intervention: FuF labels, no signage
Number of subjects: 153
Study 27745562 — intervention group
Group type: EXPERIMENTAL
Intervention: MTL labels with in‐aisle signage
Number of subjects: 153
Study 27745562 — intervention group
Group type: EXPERIMENTAL
Intervention: MTL labels, no signage
Number of subjects: 153
Study 27745562 — intervention group
Group type: COMPARATOR
Intervention: Control group, no labels/signage
Number of subjects: 153
Study 25963481 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pradigastat with a high-fat meal
Number of subjects: 24
Study 25963481 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pradigastat with a low-fat meal
Number of subjects: 24
Study 25963481 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pradigastat with a high-fat meal
Number of subjects: 24
Study 25963481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradigastat with a meal (pooled data from 13 studies)
Number of subjects: 24
Study 25963481 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted or fed conditions (both 20 and 40 mg doses)
Number of subjects: 24
Study 23571515 — intervention group
Group type: EXPERIMENTAL
Intervention: High-PEEP strategy
Number of subjects: 52
Study 23571515 — intervention group
Group type: COMPARATOR
Intervention: Low-PEEP strategy
Number of subjects: 52
Study 21640879 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with fixed appliances (bands and brackets)
Number of subjects: 24
Study 20110014 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 37.5 mg tablets (study A)
Number of subjects: 36
Study 20110014 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg tablets (study B)
Number of subjects: 36
Study 20110014 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 225 mg tablet (study C)
Number of subjects: 36
Study 20110014 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 150 mg + 75 mg capsules (study D)
Number of subjects: 36
Study 16304557 — intervention group
Group type: EXPERIMENTAL
Intervention: alfuzosin (10 or 15 mg) once daily for 3 months
Number of subjects: 536
Study 16304557 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 536
Study 15346071 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted knee navigation system (Group N)
Number of subjects: 64
Study 15346071 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty without navigation (Group C)
Number of subjects: 64
Study 11459681 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar needles with large needle movement
Number of subjects: 48
Study 11459681 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric needles with small needle movements (1 mm or less)
Number of subjects: 48
Study 11459681 — intervention group
Group type: COMPARATOR
Intervention: Standard insertion technique with large needle movement
Number of subjects: 48
Study 11459681 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle handling technique with small needle movements
Number of subjects: 48
Study 9292243 — intervention group
Group type: EXPERIMENTAL
Intervention: Finapres systolic pressure
Number of subjects: 10
Study 9292243 — intervention group
Group type: EXPERIMENTAL
Intervention: Finapres diastolic pressure
Number of subjects: 10
Study 9292243 — intervention group
Group type: COMPARATOR
Intervention: Beta‐adrenoceptor blockade with propranolol (160 mg)
Number of subjects: 10
Study 9292243 — intervention group
Group type: COMPARATOR
Intervention: Beta‐adrenoceptor modulation with celiprolol (400 mg)
Number of subjects: 10
Study 9244644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 60
Study 9244644 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 60
Study 2576327 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline and beta-adrenergic agonists combination
Number of subjects: 0
Study 1119820 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% colchicine in hydrophilic ointment applied once daily for 6 to 12 weeks
Number of subjects: 0
Study 1119820 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% and 0.50% colchicine with occlusion
Number of subjects: 0
Study 1119820 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic petrolatum (thick viscous base)
Number of subjects: 0
Study 31765315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast optic flow speed during RATW
Number of subjects: 28
Study 31765315 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow optic flow speed during RATW in Hallway group
Number of subjects: 28
Study 31765315 — intervention group
Group type: COMPARATOR
Intervention: Optic flow speed manipulation (both slow and fast)
Number of subjects: 28
Study 31765315 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR during RATW
Number of subjects: 28
Study 31202270 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended psychosocial support program based on Acceptance and Commitment Therapy
Number of subjects: 23
Study 28431047 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 3280
Study 28431047 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 3280
Study 28431047 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score II
Number of subjects: 3280